ONCS - オンコセク・メディカル (OncoSec Medical Incorporated) オンコセク・メディカル

 ONCSのチャート


 ONCSの企業情報

symbol ONCS
会社名 OncoSec Medical Inc (オンコセク・メディカル)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 OncoSec Medical Incorporated is a biotechnology company. The Company is focused on designing developing and commercializing gene therapies therapeutics and medical approaches to stimulate an anti-tumor immune response for the treatment of cancer. The Company's lead product candidate ImmunoPulse IL-12 consists of a plasmid construct encoding the proinflammatory cytokine IL-12 which is delivered into the tumor through in vivo electroporation. As of July 31 2016 the Company was pursuing two Phase II trials: ImmunoPulse IL-12 monotherapy in patients with metastatic melanoma and ImmunoPulse IL-12 plus pembrolizumab in patients with advanced metastatic melanoma. In addition it is pursuing ImmunoPulse IL-12 monotherapy in patients with triple negative breast cancer. Its ImmunoPulse product candidates are based on its deoxyribonucleic acid (DNA)-based immunotherapy technology which is designed to stimulate the human immune system resulting in systemic anti-tumor immune responses.   オンコセク・メディカルは米国のバイオテクノロジ―企業。固形腫瘍の治療のための医療的アプロ―チ(主に免疫療法)の発見、開発、実用化に従事する。同社の治験プラットフォ―ムであるImmunoPulsは、DNAに基づく治療薬を直接的に腫瘍に局所送達および取り込みを行うように設計されている。2011年設立、本社はサンディエゴ。   
本社所在地 3565 General Atomics Court Suite 100 San Diego CA 92121 USA
代表者氏名 Avtar S. Dhillon Avtar S. Dhillon
代表者役職名 Independent Chairman of the Board
電話番号 +1 858-210-7333
設立年月日 39479
市場名 NASDAQ Small Cap
ipoyear ―年
従業員数 35人
url www.oncosec.com
nasdaq_url https://www.nasdaq.com/symbol/oncs
adr_tso
EBITDA EBITDA(百万ドル) -29.01532
終値(lastsale) 1.59
時価総額(marketcap) 83227931.49
時価総額 時価総額(百万ドル) 84.27482
売上高 売上高(百万ドル) 0.00000
企業価値(EV) 企業価値(EV)(百万ドル) 53.99075
当期純利益 当期純利益(百万ドル) -32.59503
決算概要 決算概要 BRIEF: For the nine months ended 30 April 2018 OncoSec Medical Inc revenues was not reported. Net loss increased 72% to $26.7M. Basic Earnings per Share excluding Extraordinary Items increased from -$0.79 to -$0.77.

 ONCSのテクニカル分析


 ONCSのニュース

   80 Biggest Movers From Yesterday  2020/12/18 09:47:14 Benzinga
Gainers Scopus BioPharma Inc. (NASDAQ: SCPS ) shares climbed 473.7% to close at $33.96 on Thursday. Scopus BioPharma’s filing showed registration for 500,000 share common stock offering. Scopus Biopharma shares gained around 8% on Wednesday after the company priced its IPO at $5.5 per share. MingZhu Logistics Holdings Ltd (NASDAQ: YGMZ ) shares surged 336.4% to close at $17.50. Wunong Net Technology Company Limited (NASDAQ: WNW ) shares climbed 88.2% to close at $122.50 after jumping 440% on Wednesday. The company, on Tuesday, priced its IPO at $5 per share. Nxt-ID, Inc. (NASDAQ: NXTD ) gained 54.2% to close at $1.4250 after jumping around 90% on Wednesday. Avenue Therapeutics, Inc. (NASDAQ: ATXI ) jumped 47.7% to close at $5.45 after the company issued regulatory update for IV Tramadol. Boqii Holding Limited (NYSE: BQ ) rose 46.1% to close at $7.00. Vivos Therapeutics, Inc. (NASDAQ: VVOS ) gained 34.4% to close at $9.11. Vivos Therapeutics, earlier during the month, priced its IPO at $6 a share.
   OncoSec Strengthens IP Portfolio with Allowance of Two European Patent Applications Covering TAVO™ and Its Gene Electrotransfer Technology  2020/12/10 14:00:00 PR Newswire
PENNINGTON, N.J. and SAN DIEGO, Dec. 10, 2020 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec") today announced that the European Patent Office has issued notices of intention to grant for two patent applications. The applications are directed to the…
   Emerald Bioscience Creates Unique Path to Prevent Blindness Using Patented Synthetic Cannabinoids  2020/12/05 03:17:21 Benzinga
The rapid innovation and growth in biotechnology is being used to define, validate, and enhance therapeutic outcomes from cannabinoids. The results could prove highly valuable to patients, as well as the pharmaceutical sector and its investors. That is according to Punit Dhillon, the recently appointed CEO at Emerald Bioscience Inc (OTC: EMBI ), a San Diego-based biotech focused on cannabinoid-derived therapies for a spectrum of diseases with unmet medical needs. Through his various leadership roles at biopharmaceutical companies like OncoSec Medical Inc (NASDAQ: ONCS ) and Inovio Pharmaceuticals Inc (NASDAQ: INO ), Dhillon learned first-hand what it takes for biotech businesses to catalyze growth and provide well-differentiated approaches for the treatment of diseases. Dhillon spoke with Benzinga about Emerald's proprietary technology which substantially enhances the local delivery, bioavailability, dosing, and – most importantly – potentially advantageous therapeutic effects of cannabinoids for diseases like glaucoma.
   OncoSec Announces Publication in International Journal of Surgery Case Reports  2020/12/03 14:00:00 PR Newswire
PENNINGTON, N.J. and SAN DIEGO, Dec. 3, 2020 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec"), a late-stage biotechnology company developing intratumoral cancer immunotherapies, today announced the online publication of a case study investigating the…
   The Daily Biotech Pulse: Lilly Secures Additional Orders For COVID-19 Antibody Treatment, Decision Day For BioCryst, Kinnate Biopharma To Make Wall Street Debut  2020/12/03 12:46:12 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Dec. 2) Amicus Therapeutics, Inc. (NASDAQ: FOLD ) Beam Therapeutics Inc (NASDAQ: BEAM ) Bioanalytical Systems, Inc. (NASDAQ: BASI ) Cerevel Therapeutics Holdings Inc (NASDAQ: CERE ) Fate Therapeutics Inc (NASDAQ: FATE ) Generation Bio Co (NASDAQ: GBIO ) Idera Pharmaceuticals Inc (NASDAQ: IDRA ) Infinity Pharmaceuticals Inc. (NASDAQ: INFI ) Inhibrx Inc (NASDAQ: INBX ) Intellia Therapeutics Inc (NASDAQ: NTLA ) Iovance Biotherapeutics Inc (NASDAQ: IOVA ) Inspire Medical Systems Inc (NYSE: INSP ) Kymera Therapeutics Inc (NASDAQ: KYMR ) Larimar Therapeutics Inc (NASDAQ: LRMR ) Merrimack Pharmaceuticals Inc (NASDAQ: MACK ) (reacted to positive outlook for the cancer drug it sold to Ispen, which opens the possibility of realizing potential milestone payments) Myovant Sciences Ltd (NYSE: MYOV ) Ocular Therapeutix Inc (NASDAQ: OCUL ) Olema Pharmaceuticals Inc (NASDAQ: OLMA ) Oncorus Inc (NASDAQ: ONCR ) OncoSec Medical Inc (NASDAQ: ONCS ) Pfizer Inc. (NYSE: PFE ) ( announced U.K. regulatory nod for emergency use of its coronavirus vaccine candidate) Praxis Precision Medicines Inc (NASDAQ: PRAX ) Pulse Biosciences Inc (NASDAQ: PLSE ) Spero Therapeutics Inc (NASDAQ: SPRO ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Dec. 2) Histogen Inc (NASDAQ: HSTO ) Nabriva Therapeutics PLC – ADR (NASDAQ: NBRV ) (shares will trade …
   OncoSec Medical Incorporated Announces Pricing of Public Offering  2020/08/17 03:55:00 PR Newswire
SAN DIEGO and PENNINGTON, N.J., Aug. 16, 2020 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ: ONCS) (the "Company" or "OncoSec") today announced that in connection with its previously announced offering of common stock, it has entered into purchase agreements for the purchase of an…
   OncoSec Medical Incorporated Announces Proposed Public Offering of Common Stock  2020/08/15 00:42:00 PR Newswire
SAN DIEGO and PENNINGTON, N.J., Aug. 14, 2020 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ: ONCS) (the "Company" or "OncoSec") today announced that it intends to offer and sell shares of its common stock in a public offering. The offering is subject to market conditions, and there…
   The Daily Biotech Pulse: India Globalization Gets Nod For Alzheimer's Trial, Moderna's Vaccine Deal With US, Cellular Biomedicine To Go Private  2020/08/12 11:08:59 Benzinga
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 11) Allovir Inc (NASDAQ: ALVR ) Erytech Pharma SA (NASDAQ: ERYP ) Eyenovia Inc (NASDAQ: EYEN ) (announced an exclusive collaboration and licensing agreement for MicroLine and MicroPine in Greater China and South Korea) Evoke Pharma Inc (NASDAQ: EVOK ) Fortress Biotech (NASDAQ: FBIO )(reacted to its second-quarter results) GENMAB A/S/S ADR (NASDAQ: GMAB ) Inari Medical Inc (NASDAQ: NARI ) iTeos Therapeutics Inc (NASDAQ: ITOS ) Kura Oncology Inc (NASDAQ: KURA ) OncoSec Medical Inc (NASDAQ: ONCS ) Orthopediatrics Corp (NASDAQ: KIDS ) Pacira Biosciences Inc (NASDAQ: PCRX ) Rocket Pharmaceuticals Inc (NASDAQ: RCKT ) Silk Road Medical Inc (NASDAQ: SILK ) Trevi Therapeutics Inc (NASDAQ: TRVI ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Aug. 11) Burning Rock Biotech Ltd (NASDAQ: BNR )(announced its second-quarter results) Homology Medicines Inc (NASDAQ: FIXX )(reacted to its second-quarter results) Legend Biotech Corp (NASDAQ: LEGN ) Nurix Therapeutics Inc (NASDAQ: NRIX ) Stocks In Focus Moderna Clinches Deal With U.S.
   OncoSec to Present at the BTIG Virtual Biotechnology Conference 2020 on Tuesday, August 11, 2020  2020/08/10 12:30:00 PR Newswire
SAN DIEGO and PENNINGTON, N.J., Aug. 10, 2020 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ: ONCS) (the "Company" or "OncoSec"), a company developing late-stage intratumoral cancer immunotherapies, today announced that Daniel J. O'Connor, President and Chief Executive Officer will…
   The Daily Biotech Pulse: Merck's Breakthrough Therapy Designation, Sonoma Surges On Sanitizer News, Sanofi-Glaxo And More  2020/07/29 11:32:01 Benzinga
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 28) Axonics Modulation Technologies Inc (NASDAQ: AXNX ) Capricor Therapeutics Inc (NASDAQ: CAPR ) Fulgent Genetics Inc (NASDAQ: FLGT ) ITAMAR MED LTD/S ADR (NASDAQ: ITMR ) Medpace Holdings Inc (NASDAQ: MEDP ) (saw an extension of its earnings-induced momentum) NeoGenomics, Inc. (NASDAQ: NEO )(reacted to its second-quarter results) OncoSec Medical Inc (NASDAQ: ONCS ) Penumbra Inc (NYSE: PEN ) Qiagen NV (NYSE: QGEN ) TFF Pharmaceuticals Inc (NASDAQ: TFFP ) Trevena Inc (NASDAQ: TRVN ) X T L Biopharmaceuticals Ltd (NASDAQ: XTLB ) Zoetis Inc (NYSE: ZTS ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows July 28) Nkarta Inc (NASDAQ: NKTX ) Nurix Therapeutics Inc (NASDAQ: NRIX )(IPOed Friday) Verrica Pharmaceuticals Inc (NASDAQ: VRCA ) Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN ) Stocks In Focus Alector Slips After Presenting Dementia Drug Trial Results Alector Inc (NASDAQ: ALEC ) announced at the virtual 2020 Alzheimer's Association International Conference, or AAIC, preliminary results from a Phase 1b and open-label Phase 2 studies of AL001 for the treatment of people with frontotemporal dementia with a progranulin gene mutation, or FTD-GRN, with the Phase 1 study showing AL001 was generally safe and well-tolerated.
   The Daily Biotech Pulse: Opko Wins CDC Contract, Novartis Lowers Guidance, Pieris Study Placed On Partial Clinical Hold  2020/07/21 11:58:40 Benzinga Feeds
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 20) Abbott Laboratories (NYSE: ABT ) ABIOMED, Inc. (NASDAQ: ABMD ) Aclaris Therapeutics Inc (NASDAQ: ACRS ) Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ) Altimmune Inc (NASDAQ: ALT ) argenx SE – ADR (NASDAQ: ARGX ) AstraZeneca plc (NYSE: AZN ) ( announced positive Phase 1/2 readout for the coronavirus vaccine it is co-developing with the Oxford University) Bio-Rad Laboratories, Inc. Class A Common Stock (NYSE: BIO ) Bio-Rad Laboratories, Inc. Class B Common Stock (NYSE: BIO ) Beigene Ltd (NASDAQ: BGNE ) BIO-TECHNE Corp (NASDAQ: TECH ) BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) BioXcel Therapeutics Inc (NASDAQ: BTAI ) (reacted to positive late-stage readout for BXCK501 in treating schizophrenia and bipolar disorder) Brainstorm Cell Therapeutics Inc (NASDAQ: BCLI ) CALLIDITAS THER/S ADR (NASDAQ: CALT ) Catalent Inc (NYSE: CTLT ) Cytosorbents Corp Inc (NASDAQ: CTSO ) Dynavax Technologies Corporation (NASDAQ: DVAX ) Emergent Biosolutions Inc (NYSE: EBS ) Fortress Biotech (NASDAQ: FBIO ) GENMAB A/S/S ADR (NASDAQ: GMAB ) Heat Biologics Inc (NASDAQ: HTBX ) Illumina, Inc.
   The Daily Biotech Pulse: Mallinckrodt Gets FDA Panel Backing, Regulatory Setback For Tricida, Relay Therapeutics IPO  2020/07/16 12:31:22 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 15) Atossa Therapeutics Inc (NASDAQ: ATOS ) (announced results from lab studies of AT-301, its COVID-19 nasal spray drug candidate) AstraZeneca plc (NYSE: AZN ) (moved on reports that it could issue an update on its coronavirus vaccine program soon) Beigene Ltd (NASDAQ: BGNE ) Bio-Rad Laboratories, Inc. Class A Common Stock (NYSE: BIO ) Bio-Rad Laboratories, Inc. Class B Common Stock (NYSE: BIO ) Castle Biosciences Inc (NASDAQ: CSTL ) (announced publication of a study demonstrating its DecisionDx-UM test results significantly impacted treatment plan recommendations for patients with uveal melanoma) Catalent Inc (NYSE: CTLT ) Cytokinetics, Inc. (NASDAQ: CYTK ) (issued an investor update on its cardiovascular pipeline) ESSA Pharma Inc (NASDAQ: EPIX ) (announced enrollment of first patient in Phase 1 study of its prostate cancer drug) Genetic Technologies Limited (NASDAQ: GENE ) (issued an update on its COVID-19 Severity Risk Test) GENMAB A/S/S ADR (NASDAQ: GMAB ) Heat Biologics Inc (NASDAQ: HTBX ) Hologic, Inc.
   The Daily Biotech Pulse: Moderna To Kickstart Phase 3 Study On July 27, Immutep Awarded Antibody Patent  2020/07/15 11:30:17 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 14) Altimmune Inc (NASDAQ: ALT ) (priced its $115 million worth of common stock and pre-funded warrant offering) Beigene Ltd (NASDAQ: BGNE ) Bicycle Therapeutics PLC (NASDAQ: BCYC ) Bio-Rad Laboratories, Inc. (NYSE: BIO ) Imv Inc (NASDAQ: IMV ) (provided an update on its coronavirus vaccine program) INmune Bio Inc (NASDAQ: INMB )( announced positive interim Phase 1b data for its Alzheimer's drug) OncoSec Medical Inc (NASDAQ: ONCS ) Qiagen NV (NYSE: QGEN ) Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL ) (announced initiation of clinical study of its fostamatinib for treating COVID-19 pneumonia) TIZIANA LF SCIE/S ADR (NASDAQ: TLSA ) Vaxart Inc (NASDAQ: VXRT ) VBI Vaccines Inc (NASDAQ: VBIV ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows July 14) Acorda Therapeutics Inc (NASDAQ: ACOR ) AnPac Bio-Medical Science Co Ltd – ADR (NASDAQ: ANPC ) BELLUS Health Inc (NASDAQ: BLU ) Brickell Biotech Inc (NASDAQ: BBI ) Forma Therapeutics Holdings Inc (NASDAQ: FMTX )(IPO quiet period expired) Genfit SA (NASDAQ: GNFT ) Gritstone Oncology Inc (NASDAQ: GRTS ) Intercept Pharmaceuticals Inc (NASDAQ: ICPT ) INVENTIVA SA/ADR (NASDAQ: IVA ) (IPOed Friday) Iterum Therapeutics PLC (NASDAQ: ITRM ) NanoVibronix Inc (NASDAQ: NAOV ) Nkarta Inc (NASDAQ: NKTX ) (IPOed Friday) Oncternal Therapeutics Inc (NASDAQ: ONCT ) Orchard Therapeutics PLC – ADR (NASDAQ: ORTX ) ORIC Pharmaceuticals Inc (NASDAQ: ORIC ) Poseida Therapeutics, Inc.
   OncoSec Presents Two Late-Breaking Abstracts on TAVO-PLUS at the American Association for Cancer Research (AACR) Virtual Annual Meeting II  2020/06/22 13:05:00 PR Newswire
-New Data Highlights the Flexibility of OncoSec's Therapeutic Platform to Enable Greater Anti-Tumor Activity with the Next-Generation TAVOPLUS IL-12 Plasmid PENNINGTON, N.J. and SAN DIEGO, June 22, 2020 /PRNewswire/ -- OncoSec Medical Incorporated (the "Company" or "OncoSec") (Nasdaq:…
   OncoSec to Present at Virtual Summer Investor Summit  2020/06/04 13:00:00 PR Newswire
PENNINGTON, N.J. and SAN DIEGO, June 4, 2020 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec"), a company developing late-stage intratumoral cancer immunotherapies, today announced that Daniel J. O'Connor, President and Chief Executive Officer of…

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 オンコセク・メディカル ONCS OncoSec Medical Incorporated)

 twitter  (公式ツイッターやCEOツイッターなど)